Search

Your search keyword '"Salazar, Oliver"' showing total 13 results
Start Over Author "Salazar, Oliver"
13 results on '"Salazar, Oliver"'

5. An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry

Author

Ergisi, Mehmet, primary, Erridge, Simon, additional, Harris, Michael, additional, Kawka, Michal, additional, Nimalan, Devaki, additional, Salazar, Oliver, additional, Loupasaki, Katerina, additional, Ali, Rayyan, additional, Holvey, Carl, additional, Coomber, Ross, additional, Usmani, Azfer, additional, Sajad, Mohammed, additional, Beri, Sushil, additional, Hoare, Jonathan, additional, Khan, Shaheen A., additional, Weatherall, Mark W., additional, Platt, Michael, additional, Rucker, James J., additional, and Sodergren, Mikael H., additional

Published
2022
Full Text
View/download PDF

6. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder

Author

Ergisi, Mehmet, primary, Erridge, Simon, additional, Harris, Michael, additional, Kawka, Michal, additional, Nimalan, Devaki, additional, Salazar, Oliver, additional, Loupasaki, Katerina, additional, Ali, Rayyan, additional, Holvey, Carl, additional, Coomber, Ross, additional, Platt, Michael, additional, Rucker, James J, additional, and Sodergren, Mikael H, additional

Published
2022
Full Text
View/download PDF

7. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions

Author

Harris, Michael, primary, Erridge, Simon, additional, Ergisi, Mehmet, additional, Nimalan, Devaki, additional, Kawka, Michal, additional, Salazar, Oliver, additional, Ali, Rayyan, additional, Loupasaki, Katerina, additional, Holvey, Carl, additional, Coomber, Ross, additional, Usmani, Azfer, additional, Sajad, Mohammed, additional, Hoare, Jonathan, additional, Rucker, James J, additional, Platt, Michael, additional, and Sodergren, Mikael H, additional

Published
2021
Full Text
View/download PDF

10. An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients

Author

Erridge, Simon, primary, Salazar, Oliver, additional, Kawka, Michal, additional, Holvey, Carl, additional, Coomber, Ross, additional, Usmani, Azfer, additional, Sajad, Mohammed, additional, Beri, Sushil, additional, Hoare, Jonathan, additional, Khan, Shaheen, additional, Weatherall, Mark W., additional, Platt, Michael, additional, Rucker, James J., additional, and Sodergren, Mikael H., additional

Published
2021
Full Text
View/download PDF

11. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions.

Author

Harris, Michael, Erridge, Simon, Ergisi, Mehmet, Nimalan, Devaki, Kawka, Michal, Salazar, Oliver, Ali, Rayyan, Loupasaki, Katerina, Holvey, Carl, Coomber, Ross, Usmani, Azfer, Sajad, Mohammed, Hoare, Jonathan, Rucker, James J, Platt, Michael, and Sodergren, Mikael H

Subjects
CHRONIC pain, MEDICAL marijuana, PAIN management, CHRONIC diseases, MEDICAL registries, BRIEF Pain Inventory
Abstract

To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs). A case series was performed using patients with chronic pain from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. Statistical significance was defined at p-value<0.050. 190 patients were included. Median initial Δ9-tetrahydrocannabinol and cannabidiol daily doses were 2.0mg (range:0.0–442.0mg) and 20.0mg (range:0.0–188.0mg) respectively. Significant improvements were observed within BPI, SF-MPQ-2, GAD-7, SQS, EQ-5D-5 L index, and VAS measures at all timepoints (p<0.050). Seventy-five adverse events (39.47%) were reported, of which 37 (19.47%) were rated as mild, 23 (12.11%) as moderate, and 14 (7.37%) as severe. Nausea (n=11; 5.8%) was the most frequent adverse event. An association was identified between patients with chronic pain prescribed CBMPs and improvements in pain-specific and general HRQoL outcomes. Most adverse events were mild to moderate in severity, indicating CBMPs were well tolerated. Inherent limitations of study design limit its overall applicability. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results